Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients

Maia Norman, Tal Gilboa, Alana F. Ogata, Adam M. Maley, Limor Cohen, Yongfei Cai, Jun Zhang, Jared E. Feldman, Blake M. Hauser, Timothy M. Caradonna, Bing Chen, Aaron G. Schmidt, Galit Alter, Richelle C. Charles, Edward T. Ryan, David R. Walt
doi: https://doi.org/10.1101/2020.04.28.20083691
Maia Norman
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
3Tufts University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tal Gilboa
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alana F. Ogata
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam M. Maley
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Limor Cohen
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
5Department of Chemical Biology, Harvard University, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongfei Cai
6Division of Molecular Medicine, Boston Children’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Zhang
6Division of Molecular Medicine, Boston Children’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared E. Feldman
7Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blake M. Hauser
7Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy M. Caradonna
7Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bing Chen
6Division of Molecular Medicine, Boston Children’s Hospital, Boston, MA
8Department of Pediatrics, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron G. Schmidt
7Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
9Department of Microbiology, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galit Alter
7Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richelle C. Charles
10Division of Infection Diseases, Massachusetts General Hospital, Boston, MA
11Department of Medicine, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward T. Ryan
10Division of Infection Diseases, Massachusetts General Hospital, Boston, MA
11Department of Medicine, Harvard Medical School, Boston, MA
12Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Walt
1Department of Pathology, Brigham and Women’s Hospital, Boston, MA
2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dwalt@bwh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The COVID-19 pandemic continues to infect millions of people worldwide. In order to curb its spread and reduce morbidity and mortality, it is essential to develop sensitive and quantitative methods that identify infected individuals and enable accurate population-wide screening of both past and present infection. Here we show that Single Molecule Array assays detect seroconversion in COVID-19 patients as soon as one day after symptom onset using less than a microliter of blood. This multiplexed assay format allows us to quantitate IgG, IgM and IgA immunoglobulins against four SARS-CoV-2 targets, thereby interrogating 12 antibody isotype-viral protein interactions to give a high resolution profile of the immune response. Using a cohort of samples collected prior to the outbreak as well as samples collected during the pandemic, we demonstrate a sensitivity of 86% and a specificity of 100% during the first week of infection, and 100% sensitivity and specificity thereafter. This assay should become the gold standard for COVID19 serological profiling and will be a valuable tool for answering important questions about the heterogeneity of clinical presentation seen in the ongoing pandemic.

Competing Interest Statement

David Walt has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company and also serves on its Board of Directors. Dr. Walt’s interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies. The assays in this publication have been licensed by Brigham and Women’s Hospital to Quanterix Corporation.

Funding Statement

This work was largely funded through a grant from the Massachusetts Consortium for Pathogen Resilience. In addition, support came from the Global TravEpiNet (GTEN) system sponsored by the US Centers for Disease Control and Prevention (Grant No. U01CK000490: ETR, RCC) as well as a T32GM007753 grant from NIGMS, a T32 AI007245 from NIAID, and an R01AI146779 from NIAID.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary information files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
Maia Norman, Tal Gilboa, Alana F. Ogata, Adam M. Maley, Limor Cohen, Yongfei Cai, Jun Zhang, Jared E. Feldman, Blake M. Hauser, Timothy M. Caradonna, Bing Chen, Aaron G. Schmidt, Galit Alter, Richelle C. Charles, Edward T. Ryan, David R. Walt
medRxiv 2020.04.28.20083691; doi: https://doi.org/10.1101/2020.04.28.20083691
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
Maia Norman, Tal Gilboa, Alana F. Ogata, Adam M. Maley, Limor Cohen, Yongfei Cai, Jun Zhang, Jared E. Feldman, Blake M. Hauser, Timothy M. Caradonna, Bing Chen, Aaron G. Schmidt, Galit Alter, Richelle C. Charles, Edward T. Ryan, David R. Walt
medRxiv 2020.04.28.20083691; doi: https://doi.org/10.1101/2020.04.28.20083691

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (524)
  • Anesthesia (125)
  • Cardiovascular Medicine (1432)
  • Dentistry and Oral Medicine (219)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10326)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2652)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (680)
  • Hematology (269)
  • HIV/AIDS (570)
  • Infectious Diseases (except HIV/AIDS) (12116)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (274)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2478)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (496)
  • Occupational and Environmental Health (569)
  • Oncology (1332)
  • Ophthalmology (403)
  • Orthopedics (151)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (344)
  • Pediatrics (785)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2417)
  • Public and Global Health (5029)
  • Radiology and Imaging (900)
  • Rehabilitation Medicine and Physical Therapy (533)
  • Respiratory Medicine (687)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)